High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS.

Abstract

Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoural Gal-1 expression by immunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumour microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval CI, 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95% CI, 30-64, P = .021). In univariate analyses age 60 or younger, non-elevated lactate dehydrogenase (LDH), and performance score less than 2 correlated with superior survival but high Gal-1 expression significantly predicted adverse outcome at both univariate (HR 2.5, 95% CI, 1.1-5.7, P = .026) and multivariate levels (HR 3.2, 95% CI, 1.2-8.5, P = .017). Tumours with high Gal-1 had few cytotoxic T cells in the tumour microenvironment. High intratumoural Gal-1 expression before therapeutic intervention correlates with adverse outcome in nodal CD30+ , ALK- PTCL patients.

• Authors: Johanne Marie Holst, Maja Ludvigsen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, Trine Lindhardt Plesner, Peter Nørgaard, Michael B Møller, Torben Steiniche, Gabriel A Rabinovich, Francesco d'Amore, Martin Bjerregård Pedersen
• Journal: Hematological oncology (Hematol Oncol) Vol. 38 Issue 1 Pg. 59-66 (Feb 2020) ISSN: 1099-1069 [Electronic] England
• PMID: 31834627 (Publication Type: Journal Article)
• Copyright: © 2019 John Wiley & Sons Ltd.

Chemical References

• Galectin 1
• Ki-1 Antigen
• LGALS1 protein, human
• ALK protein, human
• Anaplastic Lymphoma Kinase

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anaplastic Lymphoma Kinase (metabolism)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Female
• Follow-Up Studies
• Galectin 1 (metabolism)
• Humans
• Ki-1 Antigen (metabolism)
• Lymphoma, Large-Cell, Anaplastic (drug therapy, metabolism, mortality, pathology)
• Lymphoma, T-Cell, Peripheral (drug therapy, metabolism, mortality, pathology)
• Male
• Middle Aged
• Prognosis
• Retrospective Studies
• Survival Rate
• T-Lymphocytes, Cytotoxic (immunology)
• Tumor Microenvironment
• Young Adult